Crossmark

Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance

Crossref DOI link: https://doi.org/10.1016/j.aohep.2023.100899

Published Print: 2023-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Hill, Deanna D.

Kramer, Jennifer R.

Chaffin, Kassie R.

Mast, T. Christopher

Robertson, Michael N.

Kanwal, Fasiha

Haber, Barbara A.
License Information

Text and Data Mining valid from 2023-03-01

Text and Data Mining valid from 2023-03-01

Version of Record valid from 2023-01-04
More Information

This article is maintained by: Elsevier

Article Title: Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance

Journal Title: Annals of Hepatology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.aohep.2023.100899

Content Type: article

Copyright: © 2023 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Spain.